4 minute read
Jul. 24, 2023

A diaziridine-based tumor-activated prodrug for AKR1C3-expressing cancers from a defunct Bay Area biotech.


IV AKR1C3-activated cytotoxin prodrug Ph. I/II in advanced solid tumors prodrug of DNA cross-linking agent Br. J. Cancer, May 12, 2023 OBI Pharma, TW; Threshold Pharma, CA


MOTY Nominees

Molecule of the Year